INDIANAPOLIS, May 31, 2011 (GLOBE NEWSWIRE) -- Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, will be exhibiting at the Society of Nuclear Medicine (SNM) Annual Meeting, to be held in San Antonio, TX, June 4th through 8th, 2011.
Patrick G. Rooney, CEO of Positron, stated, "With the increased interest in cardiac PET and the launch of the PosiRx system, our participation at well-respected forums such as SNM is crucial to meeting customers and creating market awareness. After attendance at the American College of Cardiologists conference in April and the more recent International Conference of Non-Cardiovascular Imaging in Europe, we have seen a notable increase in interest levels for both the cardiac PET and SPECT pharmaceutical segments of our business. The exposure and introductions gained from these industry conferences have yielded opportunities that will advance our future growth."
Founded in 1954, the SNM is an international scientific and professional organization that promotes the science, technology and practical application of nuclear medicine. Its 16,000 members are physicians, technologists and scientists that specialize in the research and practice of nuclear medicine. The Society maintains an active advocacy program which promotes and encourages research for the advancement of nuclear medicine science, producing a number of programs to help physicians and technologists remain current on latest advancements. The Society also sponsors educational programs for consumers to help them understand nuclear medicine and the constructive role it can play in both diagnostic and therapeutic therapies.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron Corporation, a pioneer in molecular imaging for more than 25 years provides unique solutions for the nuclear medicine community through the production and distribution of proprietary PET molecular imaging systems and PET & SPECT radiopharmaceutical products. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (317) 576-0183.